164 related articles for article (PubMed ID: 27617940)
1. Nilontinib induced keratosis pilaris atrophicans.
Khetarpal S; Sood A; Billings SD
Dermatol Online J; 2016 Aug; 22(8):. PubMed ID: 27617940
[TBL] [Abstract][Full Text] [Related]
2. Keratosis pilaris-like eruption secondary to nilotinib in a child.
Oro-Ayude M; Feito M; Quintana-Castanedo L; Beato-Merino MJ; De Lucas R
Pediatr Dermatol; 2020 Sep; 37(5):968-969. PubMed ID: 32602176
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
[TBL] [Abstract][Full Text] [Related]
4. Nilotinib-induced generalized keratosis pilaris: Report of a rare case.
Kowe PA; Wankhade VH; Malpani SS; Singh RP
Indian J Pharmacol; 2021; 53(4):330-331. PubMed ID: 34414913
[No Abstract] [Full Text] [Related]
5. A case of new onset keratosis pilaris after discontinuation of erlotinib.
Okereke UR; Colozza S; Cohen DE
J Drugs Dermatol; 2014 Nov; 13(11):1410-1. PubMed ID: 25607711
[TBL] [Abstract][Full Text] [Related]
6. Keratosis pilaris rubra with mucin deposition.
Hosking AM; Elsensohn A; Makdisi J; Grando S; de Feraudy S
J Cutan Pathol; 2018 Dec; 45(12):958-961. PubMed ID: 30280406
[TBL] [Abstract][Full Text] [Related]
7. Keratosis pilaris-like eruption induced by nilotinib.
Jimenez-Cauhe J; Fernandez-Gonzalez P; Ortega-Quijano D; Fernandez-Nieto D; Saceda-Corralo D
Ital J Dermatol Venerol; 2021 Dec; 156(Suppl. 1 to No. 6):47-48. PubMed ID: 31302976
[No Abstract] [Full Text] [Related]
8. Generalized keratosis pilaris-like eruptions in a chronic myelogenous leukemia patient treated with nilotinib.
Shimizu A; Hattori M; Takeuchi Y; Ishikawa O
J Dermatol; 2016 Sep; 43(9):1100-1. PubMed ID: 27028020
[No Abstract] [Full Text] [Related]
9. Unilateral generalized keratosis pilaris following pregnancy.
Zhu JW; Lu ZF; Zheng M
Cutis; 2014 Oct; 94(4):203-5. PubMed ID: 25372256
[TBL] [Abstract][Full Text] [Related]
10. Trias of keratosis pilaris, ulerythema ophryogenes and 18p monosomy: Zouboulis syndrome.
Liakou AI; Esteves de Carvalho AV; Nazarenko LP
J Dermatol; 2014 May; 41(5):371-6. PubMed ID: 24801913
[TBL] [Abstract][Full Text] [Related]
11. Eyebrow reconstruction in dormant keratosis pilaris atrophicans.
Miranda BH; Farjo N; Farjo B
J Plast Reconstr Aesthet Surg; 2011 Dec; 64(12):e303-5. PubMed ID: 21723799
[TBL] [Abstract][Full Text] [Related]
12. Sebaceous gland, hair shaft, and epidermal barrier abnormalities in keratosis pilaris with and without filaggrin deficiency.
Gruber R; Sugarman JL; Crumrine D; Hupe M; Mauro TM; Mauldin EA; Thyssen JP; Brandner JM; Hennies HC; Schmuth M; Elias PM
Am J Pathol; 2015 Apr; 185(4):1012-21. PubMed ID: 25660180
[TBL] [Abstract][Full Text] [Related]
13. And next… Adnexa: Ulerythema ophryogenes and keratosis pilaris.
Coelho De Sousa V; Pinheiro R; Cunha N; Lencastre A; Cabete J
Eur J Dermatol; 2018 Aug; 28(4):566-567. PubMed ID: 30396871
[No Abstract] [Full Text] [Related]
14. Erythromelanosis follicularis faciei--a variant of keratosis pilaris?
Volks N; Fölster-Holst R
J Dtsch Dermatol Ges; 2015 Jan; 13(1):51-4. PubMed ID: 25640498
[No Abstract] [Full Text] [Related]
15. Unilateral keratosis pilaris occurring on linear hypopigmentation patches: a new variant of keratosis pilaris in an Asian?
Ma H; Xu Q; Zhu G; Su X; Yin S; Lu C; Lai W
J Dermatol; 2015 Apr; 42(4):437-8. PubMed ID: 25753262
[No Abstract] [Full Text] [Related]
16. Photopneumatic therapy for the treatment of keratosis pilaris.
Ciliberto H; Farshidi A; Berk D; Bayliss S
J Drugs Dermatol; 2013 Jul; 12(7):804-6. PubMed ID: 23884495
[TBL] [Abstract][Full Text] [Related]
17. Keratosis Pilaris and its Subtypes: Associations, New Molecular and Pharmacologic Etiologies, and Therapeutic Options.
Wang JF; Orlow SJ
Am J Clin Dermatol; 2018 Oct; 19(5):733-757. PubMed ID: 30043128
[TBL] [Abstract][Full Text] [Related]
18. Keratosis pilaris with adjacent haemosiderin deposition: a clue to scurvy.
Tee JL; Strutton G
Pathology; 2021 Aug; 53(5):666-668. PubMed ID: 33317905
[No Abstract] [Full Text] [Related]
19. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
20. Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Patel AB; Solomon AR; Mauro MJ; Ehst BD
Dermatology; 2016; 232(1):122-5. PubMed ID: 26352467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
